Bupropion and Trazodone Combination for HSDD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no approved treatment for hypoactive sexual desire disorder (HSDD) in the United States, which affects a significant portion of the population and impacts their quality of life, with existing treatments like bupropion and trazodone showing mixed results and the need for a more effective therapeutic approach.
Innovation Solution
A therapeutic composition comprising bupropion and trazodone, administered in specific dosage ranges, is proposed to treat HSDD, along with a method that includes the use of a pharmaceutically acceptable carrier, addressing the disorder's symptoms and potential co-existing conditions like depression and sexual dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bupropion or trazodone is used separately to treat HSDD, then some improvement in sexual desire may be observed, but the treatment efficacy is limited and mixed results are obtained
Solution Approach 1:
The patent combines bupropion and trazodone into a single pharmaceutical composition for treating HSDD. The combination leverages the complementary mechanisms of action: bupropion (dopamine/norepinephrine reuptake inhibitor) and trazodone (serotonin antagonist) work synergistically to improve sexual desire more effectively than either agent alone, as demonstrated by the synergistic effect described in the patent
Solution Approach 2:
The patent creates a composite pharmaceutical formulation containing both bupropion and trazodone. This composite approach allows the two drugs to work together to address multiple neurotransmitter systems involved in sexual desire regulation, providing a more comprehensive and reliable treatment than monotherapy
2Device complexity
If existing single-drug treatments are used for HSDD, then treatment can be simple, but the results are inconsistent and often insufficient
Solution Approach 1:
The patent merges bupropion and trazodone into a fixed-ratio pharmaceutical composition, providing a consistent and reliable treatment regimen. This combination formulation ensures that patients receive both active ingredients in optimal proportions, improving treatment consistency while maintaining relatively simple administration (once or twice daily dosing)
Data Source
AI summary
The invention further relates to compounds, pharmaceutical compositions and methods for treating hypoactive sexual desire disorder (HSDD) in a subject.